3
Clinical Trials associated with PF-4856883A Phase 1, Randomized, Open-label, Parallel-group Study To Evaluate The Pharmacokinetics Of Pf-04856883 (Cvx-096) Following Subcutaneous Administration In Healthy Volunteers
The purpose of the study is to further evaluate the PK characteristics of PF-04856883.
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of Cvx-096 In Type 2 Diabetic Adult Subjects
The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.
100 Clinical Results associated with PF-4856883
100 Translational Medicine associated with PF-4856883
100 Patents (Medical) associated with PF-4856883
100 Deals associated with PF-4856883